CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 68736-68910 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"We recently reported that daclizumab improved pulmonary function in a phase II trial of patients with moderate to severe chronic persistent asthma (JACI, 2004, 113 (2):S286).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T5067","span":{"begin":0,"end":174},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T5067","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T167","span":{"begin":0,"end":174},"obj":"Sentence"}],"attributes":[{"subj":"T167","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T540","span":{"begin":140,"end":146},"obj":"Disease"}],"attributes":[{"id":"A540","pred":"mondo_id","subj":"T540","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"subj":"T540","pred":"source","obj":"CORD-19-PD-MONDO"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T284","span":{"begin":140,"end":146},"obj":"Phenotype"}],"attributes":[{"id":"A284","pred":"hp_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"subj":"T284","pred":"source","obj":"CORD-19-PD-HP"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ec939d","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93b7ec"},{"id":"CORD-19-PD-MONDO","color":"#d1ec93"},{"id":"CORD-19-PD-HP","color":"#ec93eb"}]}]}}